Non-resident patent applicants accounted for 90% of the patent applications received by the IP office of Australia in 2020, but only 10% of the applications received
Non-resident patent applicants accounted for 90% of the patent applications received by the IP office of Australia in 2020, but only 10% of the applications received
Tiffany Norwood is successful entrepreneur, creator, Wall Street financier and educator. She also on a mission to help others succeed. The 2022 Entrepreneur of the Year recipient
A bastion of business coverage of large corporations since the 1920s, Fortune Magazine, lambasted BigTech companies because they “acquire and kill competitors and copy other
The Battle for Google Earth — It sounds like a science fiction movie, doesn’t it? It is more of a fact-based crime drama that provides
In the latest episode of ‘Understanding IP Maters,’ the podcast that looks at the IP stories of creators who became successful entrepreneurs, movie producer and
Frederick Shelton IV, arguably the most prolific and financially successful inventors ever, is a Johnson & Johnson medical device innovator unknown to pretty much everyone
In the decade since the adoption of the America Invents Act (AIA) patent licensing has become more arduous for many technology companies and independent inventors.
In the latest episode of ‘Understanding IP Matters’, which dropped today on leading podcast platforms, award-winning inventor Dan Brown says that the patent winds have shifted and are blowing
IP CloseUp celebrated its Tenth Anniversary in 2021, with viewership up 44% since 2018. Annual increases since 2018 were 7%, 11 % and 21%, respectively. The 2021
Nine companies were added for the first time to Clarivate’s 2021 list of the Top 100 Global Innovators, including a few relatively unknowns: BorgWarner, ASUS, Bose,
With the backing of leading private equity funds and record labels, celebrity singer-song writers such as Bob Dylan, Prince and Neil Young, are cashing in on strong long-term demand
Researchers’ unprecedented rapid response to the Covid-19 pandemic and that of the bio-pharmaceutical companies – which included sharing proprietary technology with many dozens of partners